Cargando…
Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma
Multiple Myeloma (MM) is an incurable neoplasm of mature B cells and the second most prevalent hematological malignancy worldwide. While combinations of proteasome inhibitors like bortezomib (Bz) and immunomodulators (IMiDs) like lenalinomide (Len) are generally effective in newly diagnosed patients...
Autores principales: | Domenger, Antoine, Ricci, Daniela, Mayau, Véronique, Majlessi, Laleh, Marcireau, Christophe, Dadaglio, Gilles, Demangel, Caroline |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911829/ https://www.ncbi.nlm.nih.gov/pubmed/36776330 http://dx.doi.org/10.3389/fonc.2023.1110916 |
Ejemplares similares
-
The Sec61 translocon is a therapeutic vulnerability in multiple myeloma
por: Domenger, Antoine, et al.
Publicado: (2022) -
Mycolactone subverts immunity by selectively blocking the Sec61 translocon
por: Baron, Ludivine, et al.
Publicado: (2016) -
Proteasome 19S RP Binding to the Sec61 Channel Plays a Key Role in ERAD
por: Kaiser, Marie-Luise, et al.
Publicado: (2015) -
Loopy Sec61 mutants
por: LeBrasseur, Nicole
Publicado: (2005) -
Complexity and Specificity of Sec61-Channelopathies: Human Diseases Affecting Gating of the Sec61 Complex
por: Sicking, Mark, et al.
Publicado: (2021)